Details of the Drug

General Information of Drug (ID: DMWSMND)

Drug Name
Cevimeline
Synonyms
Evoxac; Saligren; Cevimeline [INN]; Cevimeline hydrochloride; Cevimeline hydrochloride [USAN]; Cevimeline hydrochloride hemihydrate; Cevimeline hydrochloride hydrate; AF 102B; AF102B; Fks 508; AF-102B; Cevimeline (INN); Cevimeline HCl 1/2H2O; Cevimeline hydrochloride (USAN); Cevimeline hydrochloride hydrate (JAN); Cevimeline.HCl; Evoxac (TN); FKS-508; SND-5008; SNI-2011; SNK-508; Saligren (TN); SND 5008, AF-102B, FKS-508; Cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1); (+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate; (+/-)-cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride; (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride; 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
Indication
Disease Entry ICD 11 Status REF
Sjogren syndrome 4A43.20 Approved [1]
Therapeutic Class
Parasympathomimetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 199.32
Topological Polar Surface Area (xlogp) 1.5
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Elimination
13.5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 +/- 1 hours [3]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.05139 micromolar/kg/day [5]
Vd
The volume of distribution (Vd) of drug is 6 L/kg [6]
Chemical Identifiers
Formula
C10H17NOS
IUPAC Name
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
Canonical SMILES
C[C@@H]1O[C@]2(CN3CCC2CC3)CS1
InChI
InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1
InChIKey
WUTYZMFRCNBCHQ-PSASIEDQSA-N
Cross-matching ID
PubChem CID
83898
CAS Number
107233-08-9
DrugBank ID
DB00185
TTD ID
D0Q4CS
INTEDE ID
DR0294
ACDINA ID
D00117

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M3 (CHRM3) TTQ13Z5 ACM3_HUMAN Agonist [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Sjogren syndrome
ICD Disease Classification 4A43.20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Muscarinic acetylcholine receptor M3 (CHRM3) DTT CHRM3 4.61E-07 -0.59 -0.73
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cevimeline (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Troglitazone DM3VFPD Minor Increased metabolism of Cevimeline caused by Troglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [36]
Ivosidenib DM8S6T7 Minor Increased metabolism of Cevimeline caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [36]
Arn-509 DMT81LZ Minor Increased metabolism of Cevimeline caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [36]
Scopolamine DMOM8AL Moderate Antagonize the effect of Cevimeline when combined with Scopolamine. Addictive disorder [6C50-6C5Z] [37]
Mitotane DMU1GX0 Minor Increased metabolism of Cevimeline caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [36]
Ranolazine DM0C9IL Moderate Decreased metabolism of Cevimeline caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [36]
Butalbital DM9J04X Minor Increased metabolism of Cevimeline caused by Butalbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [36]
Methylphenobarbital DMDSWAG Minor Increased metabolism of Cevimeline caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [36]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Cevimeline caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [36]
Voriconazole DMAOL2S Moderate Decreased metabolism of Cevimeline caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [38]
Posaconazole DMUL5EW Moderate Decreased metabolism of Cevimeline caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [36]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Cevimeline caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [36]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Cevimeline caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Erythromycin DM4K7GQ Moderate Decreased metabolism of Cevimeline caused by Erythromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Cevimeline caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Cevimeline caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Cevimeline caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Cevimeline caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Cevimeline caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [39]
Pexidartinib DMS2J0Z Minor Increased metabolism of Cevimeline caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [36]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Cevimeline caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [40]
Secobarbital DM14RF5 Minor Increased metabolism of Cevimeline caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [36]
Tiotropium DMFDC0Q Moderate Antagonize the effect of Cevimeline when combined with Tiotropium. Chronic obstructive pulmonary disease [CA22] [37]
Ipratropium DMFQ320 Moderate Antagonize the effect of Cevimeline when combined with Ipratropium. Chronic obstructive pulmonary disease [CA22] [37]
Revefenacin DMMP5SI Moderate Antagonize the effect of Cevimeline when combined with Revefenacin. Chronic obstructive pulmonary disease [CA22] [37]
Phenylbutazone DMAYL0T Minor Increased metabolism of Cevimeline caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [36]
Methadone DMTW6IU Moderate Decreased metabolism of Cevimeline caused by Methadone mediated inhibition of CYP450 enzyme. Cough [MD12] [36]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Cevimeline caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [36]
Aminoglutethimide DMWFHMZ Minor Increased metabolism of Cevimeline caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [36]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Cevimeline caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [41]
MK-8228 DMOB58Q Moderate Decreased metabolism of Cevimeline caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [36]
Aprepitant DM053KT Moderate Decreased metabolism of Cevimeline caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [42]
Sertraline DM0FB1J Moderate Decreased metabolism of Cevimeline caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [36]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Cevimeline caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [36]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Cevimeline caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [36]
Paroxetine DM5PVQE Moderate Decreased metabolism of Cevimeline caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [36]
Escitalopram DMFK9HG Moderate Decreased metabolism of Cevimeline caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [36]
Doxepin DMPI98T Moderate Decreased metabolism of Cevimeline caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [36]
Griseofulvin DMK54YG Minor Increased metabolism of Cevimeline caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [36]
Hyoscyamine DM804UR Moderate Antagonize the effect of Cevimeline when combined with Hyoscyamine. Digestive system disease [DE2Z] [37]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Cevimeline when combined with Mepenzolate. Digestive system disease [DE2Z] [37]
Citalopram derivative 1 DMITX1G Moderate Decreased metabolism of Cevimeline caused by Citalopram derivative 1 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [36]
Oxybutynine DMJPBAX Moderate Antagonize the effect of Cevimeline when combined with Oxybutynine. Discovery agent [N.A.] [37]
Meclizine DMS7T13 Moderate Antagonize the effect of Cevimeline when combined with Meclizine. Dizziness and giddiness [MB48] [37]
Trihexyphenidyl DMB19L8 Moderate Antagonize the effect of Cevimeline when combined with Trihexyphenidyl. Dystonic disorder [8A02] [37]
Fenfluramine DM0762O Moderate Decreased metabolism of Cevimeline caused by Fenfluramine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Primidone DM0WX6I Minor Increased metabolism of Cevimeline caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Felbamate DM1V5ZS Minor Increased metabolism of Cevimeline caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Oxcarbazepine DM5PU6O Minor Increased metabolism of Cevimeline caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Cenobamate DMGOVHA Minor Increased metabolism of Cevimeline caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Stiripentol DMMSDOY Moderate Decreased metabolism of Cevimeline caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Phenytoin DMNOKBV Minor Increased metabolism of Cevimeline caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Fosphenytoin DMOX3LB Minor Increased metabolism of Cevimeline caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Phenobarbital DMXZOCG Minor Increased metabolism of Cevimeline caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Carbamazepine DMZOLBI Minor Increased metabolism of Cevimeline caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Eslicarbazepine DMZREFQ Minor Increased metabolism of Cevimeline caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Diphenhydramine DMKQTBA Moderate Decreased metabolism of Cevimeline caused by Diphenhydramine mediated inhibition of CYP450 enzyme. Episodic vestibular syndrome [AB31] [36]
Tropicamide DM1D90W Moderate Antagonize the effect of Cevimeline when combined with Tropicamide. Eye anterior segment structural developmental anomaly [LA11] [37]
Tazemetostat DMWP1BH Minor Increased metabolism of Cevimeline caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [36]
Solifenacin DMG592Q Moderate Antagonize the effect of Cevimeline when combined with Solifenacin. Functional bladder disorder [GC50] [37]
Mirabegron DMS1GYT Moderate Decreased metabolism of Cevimeline caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [36]
Tolterodine DMSHPW8 Moderate Antagonize the effect of Cevimeline when combined with Tolterodine. Functional bladder disorder [GC50] [37]
Darifenacin DMWXLYZ Moderate Antagonize the effect of Cevimeline when combined with Darifenacin. Functional bladder disorder [GC50] [37]
Itraconazole DMCR1MV Moderate Decreased metabolism of Cevimeline caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Terbinafine DMI6HUW Moderate Decreased metabolism of Cevimeline caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Clotrimazole DMMFCIH Moderate Decreased metabolism of Cevimeline caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Fluconazole DMOWZ6B Moderate Decreased metabolism of Cevimeline caused by Fluconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Cevimeline caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Propantheline DM2EN6G Moderate Antagonize the effect of Cevimeline when combined with Propantheline. Gastric ulcer [DA60] [37]
Cimetidine DMH61ZB Moderate Decreased metabolism of Cevimeline caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [36]
Cyclopentolate DMA8LM5 Moderate Antagonize the effect of Cevimeline when combined with Cyclopentolate. General examination [QA00] [37]
Sulfinpyrazone DMEV954 Minor Increased metabolism of Cevimeline caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [36]
Boceprevir DMBSHMF Moderate Decreased metabolism of Cevimeline caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [36]
Telaprevir DMMRV29 Moderate Decreased metabolism of Cevimeline caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [36]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Cevimeline caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [36]
Rifampin DMA8J1G Minor Increased metabolism of Cevimeline caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [36]
Rifapentine DMCHV4I Minor Increased metabolism of Cevimeline caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [36]
Indinavir DM0T3YH Moderate Decreased metabolism of Cevimeline caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Delavirdine DM3NF5G Moderate Decreased metabolism of Cevimeline caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Cevimeline caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Nevirapine DM6HX9B Minor Increased metabolism of Cevimeline caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Cevimeline caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Efavirenz DMC0GSJ Minor Increased metabolism of Cevimeline caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Saquinavir DMG814N Moderate Decreased metabolism of Cevimeline caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Etravirine DMGV8QU Minor Increased metabolism of Cevimeline caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Cevimeline caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Darunavir DMN3GCH Moderate Decreased metabolism of Cevimeline caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Atazanavir DMSYRBX Moderate Decreased metabolism of Cevimeline caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Ritonavir DMU764S Moderate Decreased metabolism of Cevimeline caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Cevimeline caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [36]
Levamlodipine DM92S6N Moderate Decreased metabolism of Cevimeline caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [36]
Verapamil DMA7PEW Moderate Decreased metabolism of Cevimeline caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [36]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Cevimeline caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [36]
Amlodipine DMBDAZV Moderate Decreased metabolism of Cevimeline caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [36]
Conivaptan DM1V329 Moderate Decreased metabolism of Cevimeline caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [43]
Givosiran DM5PFIJ Moderate Decreased metabolism of Cevimeline caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [36]
Belladonna DM2RBWK Moderate Antagonize the effect of Cevimeline when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [37]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Cevimeline caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [44]
Amobarbital DM0GQ8N Minor Increased metabolism of Cevimeline caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [36]
Butabarbital DMC5AST Minor Increased metabolism of Cevimeline caused by Butabarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [36]
Pentobarbital DMFNH7L Minor Increased metabolism of Cevimeline caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [36]
Clidinium DMUMQZ0 Moderate Antagonize the effect of Cevimeline when combined with Clidinium. Irritable bowel syndrome [DD91] [37]
Dicyclomine DMZSDGX Moderate Antagonize the effect of Cevimeline when combined with Dicyclomine. Irritable bowel syndrome [DD91] [37]
Ticlopidine DMO946V Moderate Decreased metabolism of Cevimeline caused by Ticlopidine mediated inhibition of CYP450 enzyme. Ischaemic/haemorrhagic stroke [8B20] [36]
Crizotinib DM4F29C Moderate Decreased metabolism of Cevimeline caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [36]
PF-06463922 DMKM7EW Minor Increased metabolism of Cevimeline caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [36]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Cevimeline caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [36]
Selpercatinib DMZR15V Moderate Decreased metabolism of Cevimeline caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [36]
Lumefantrine DM29GAD Moderate Decreased metabolism of Cevimeline caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [36]
Halofantrine DMOMK1V Moderate Decreased metabolism of Cevimeline caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [36]
Chloroquine DMSI5CB Moderate Decreased metabolism of Cevimeline caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [36]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Cevimeline caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [36]
Quinine DMSWYF5 Moderate Decreased metabolism of Cevimeline caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [36]
Primaquine DMWQ16I Moderate Decreased metabolism of Cevimeline caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [36]
Idelalisib DM602WT Moderate Decreased metabolism of Cevimeline caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [36]
IPI-145 DMWA24P Moderate Decreased metabolism of Cevimeline caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [36]
Vemurafenib DM62UG5 Minor Increased metabolism of Cevimeline caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [36]
Dabrafenib DMX6OE3 Minor Increased metabolism of Cevimeline caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [36]
Danazol DML8KTN Moderate Decreased metabolism of Cevimeline caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [36]
Exjade DMHPRWG Minor Increased metabolism of Cevimeline caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [36]
Panobinostat DM58WKG Moderate Decreased metabolism of Cevimeline caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [36]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Cevimeline and Siponimod. Multiple sclerosis [8A40] [38]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Cevimeline and Fingolimod. Multiple sclerosis [8A40] [45]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Cevimeline and Ozanimod. Multiple sclerosis [8A40] [46]
Rifabutin DM1YBHK Minor Increased metabolism of Cevimeline caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [36]
Bexarotene DMOBIKY Minor Increased metabolism of Cevimeline caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [36]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Cevimeline caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [36]
Nilotinib DM7HXWT Moderate Decreased metabolism of Cevimeline caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [36]
Imatinib DM7RJXL Moderate Decreased metabolism of Cevimeline caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [36]
Dasatinib DMJV2EK Moderate Decreased metabolism of Cevimeline caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [47]
Modafinil DMYILBE Minor Increased metabolism of Cevimeline caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [48]
Dimenhydrinate DM264B3 Moderate Antagonize the effect of Cevimeline when combined with Dimenhydrinate. Nausea/vomiting [MD90] [37]
Promethazine DM6I5GR Moderate Decreased metabolism of Cevimeline caused by Promethazine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [36]
Cyclizine DM9G7BS Moderate Antagonize the effect of Cevimeline when combined with Cyclizine. Nausea/vomiting [MD90] [37]
Netupitant DMEKAYI Moderate Decreased metabolism of Cevimeline caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [36]
Bupropion DM5PCS7 Moderate Decreased metabolism of Cevimeline caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [36]
Entrectinib DMMPTLH Moderate Decreased metabolism of Cevimeline caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [36]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Cevimeline caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [36]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Cevimeline caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [36]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Cevimeline caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [36]
Dextropropoxyphene DM23HCX Moderate Decreased metabolism of Cevimeline caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [36]
Flavoxate DMKV4NL Moderate Antagonize the effect of Cevimeline when combined with Flavoxate. Pain [MG30-MG3Z] [37]
Biperiden DME78OA Moderate Antagonize the effect of Cevimeline when combined with Biperiden. Parkinsonism [8A00] [37]
Benztropine DMGZOVN Moderate Antagonize the effect of Cevimeline when combined with Benztropine. Parkinsonism [8A00] [37]
Procyclidine DMHFJDT Moderate Antagonize the effect of Cevimeline when combined with Procyclidine. Parkinsonism [8A00] [37]
Abametapir DM2RX0I Moderate Decreased metabolism of Cevimeline caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [49]
Methylscopolamine DM5VWOB Moderate Antagonize the effect of Cevimeline when combined with Methylscopolamine. Peptic ulcer [DA61] [37]
Lefamulin DME6G97 Moderate Decreased metabolism of Cevimeline caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [50]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Cevimeline caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [36]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Cevimeline caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [36]
Enzalutamide DMGL19D Minor Increased metabolism of Cevimeline caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [36]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Cevimeline caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [36]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Cevimeline caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [36]
Fluphenazine DMIT8LX Moderate Decreased metabolism of Cevimeline caused by Fluphenazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [36]
Bosentan DMIOGBU Minor Increased metabolism of Cevimeline caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [36]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Cevimeline and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [51]
Celecoxib DM6LOQU Moderate Decreased metabolism of Cevimeline caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [36]
Dexamethasone DMMWZET Minor Increased metabolism of Cevimeline caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [36]
Nafcillin DMN9RPO Minor Increased metabolism of Cevimeline caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [36]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Cevimeline caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [36]
Thioridazine DM35M8J Moderate Decreased metabolism of Cevimeline caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [36]
Haloperidol DM96SE0 Moderate Decreased metabolism of Cevimeline caused by Haloperidol mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [36]
Perphenazine DMA4MRX Moderate Decreased metabolism of Cevimeline caused by Perphenazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [36]
Chlorpromazine DMBGZI3 Moderate Decreased metabolism of Cevimeline caused by Chlorpromazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [36]
Clozapine DMFC71L Moderate Antagonize the effect of Cevimeline when combined with Clozapine. Schizophrenia [6A20] [37]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Cevimeline caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [36]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Cevimeline caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [52]
Gefitinib DM15F0X Moderate Decreased metabolism of Cevimeline caused by Gefitinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [36]
Armodafinil DMGB035 Minor Increased metabolism of Cevimeline caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [48]
LEE011 DMMX75K Moderate Decreased metabolism of Cevimeline caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [36]
Trospium DMX6RTG Moderate Antagonize the effect of Cevimeline when combined with Trospium. Tonus and reflex abnormality [MB47] [37]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Cevimeline and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [51]
Atropine DMEN6X7 Moderate Antagonize the effect of Cevimeline when combined with Atropine. Unspecific substance harmful effect [NE6Z] [37]
Elagolix DMB2C0E Minor Increased metabolism of Cevimeline caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [36]
Disopyramide DM5SYZP Moderate Antagonize the effect of Cevimeline when combined with Disopyramide. Ventricular tachyarrhythmia [BC71] [37]
Procainamide DMNMXR8 Moderate Antagonize the effect of Cevimeline when combined with Procainamide. Ventricular tachyarrhythmia [BC71] [37]
Propafenone DMPIBJK Moderate Decreased metabolism of Cevimeline caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [36]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Cevimeline caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [36]
⏷ Show the Full List of 178 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Eisenoxyd E00585 56841934 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cevimeline 30 mg capsule 30 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Therapeutic effect of cevimeline on dry eye in patients with Sj gren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004 Jul;138(1):6-17.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
8 Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
19 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
20 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
21 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
22 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
23 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
24 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
25 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
26 Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
27 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
28 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
29 Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
30 M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
31 Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
32 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
33 Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
34 Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
35 Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem. 1993 Oct 25;268(30):22436-43.
36 Product Information. Evoxac (cevimeline) Daiichi Pharmaceuticals, Fort lee, NJ.
37 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
38 Cerner Multum, Inc. "Australian Product Information.".
39 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
40 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
42 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
43 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
44 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
45 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
46 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
47 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
48 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
49 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
50 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
51 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
52 Cerner Multum, Inc. "UK Summary of Product Characteristics.".